This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Piddock, L. J. V.
Right arrow Articles by Everett, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Piddock, L. J. V.
Right arrow Articles by Everett, M. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2002, p. 2276-2278, Vol. 46, No. 7
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.7.2276-2278.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Novel Ciprofloxacin-Resistant, Nalidixic Acid-Susceptible Mutant of Staphylococcus aureus

Laura J. V. Piddock,* Yu Fang Jin, Mark A. Webber, and Martin J. Everett

Antimicrobial Agents Research Group, Division of Immunity & Infection, University of Birmingham, Birmingham B15 2TT, United Kingdom

Received 26 October 2001/ Returned for modification 15 January 2002/ Accepted 12 April 2002

A ciprofloxacin-resistant, nalidixic acid-susceptible mutant of Staphylococcus aureus (F145) contained no mutations within gyrA, gyrB, grlA, and grlB or within norA or its promoter region. MICs and accumulation studies suggest the role of a novel multidrug efflux pump.

* Corresponding author. Mailing address: Antimicrobial Agents Research Group, Division of Immunity & Infection, University of Birmingham, Birmingham B15 2TT, United Kingdom. Phone: 0121-414-6966. Fax: 0121-414-3454. E-mail: L.j.v.piddock{at}bham.ac.uk.

Antimicrobial Agents and Chemotherapy, July 2002, p. 2276-2278, Vol. 46, No. 7
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.7.2276-2278.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • SPENGLER, G., MARTINS, A., SCHELZ, Z., RODRIGUES, L., AAGAARD, L., MARTINS, M., COSTA, S. S., COUTO, I., VIVEIROS, M., FANNING, S., KRISTIANSEN, J. E., MOLNAR, J., AMARAL, L. (2009). Characterization of Intrinsic Efflux Activity of Enterococcus faecalis ATCC29212 by a Semi-automated Ethidium Bromide Method. In Vivo 23: 81-87 [Abstract] [Full Text]  
  • Hakanen, A. J., Lindgren, M., Huovinen, P., Jalava, J., Siitonen, A., Kotilainen, P. (2005). New Quinolone Resistance Phenomenon in Salmonella enterica: Nalidixic Acid-Susceptible Isolates with Reduced Fluoroquinolone Susceptibility. J. Clin. Microbiol. 43: 5775-5778 [Abstract] [Full Text]  
  • Poole, K. (2005). Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 56: 20-51 [Abstract] [Full Text]  
  • Campion, J. J., McNamara, P. J., Evans, M. E. (2004). Evolution of Ciprofloxacin-Resistant Staphylococcus aureus in In Vitro Pharmacokinetic Environments. Antimicrob. Agents Chemother. 48: 4733-4744 [Abstract] [Full Text]  
  • Perez-Vazquez, M., Roman, F., Aracil, B., Canton, R., Campos, J. (2004). Laboratory Detection of Haemophilus influenzae with Decreased Susceptibility to Nalidixic Acid, Ciprofloxacin, Levofloxacin, and Moxifloxacin Due to gyrA and parC Mutations. J. Clin. Microbiol. 42: 1185-1191 [Abstract] [Full Text]  
  • Van Bambeke, F., Glupczynski, Y., Plesiat, P., Pechere, J. C., Tulkens, P. M. (2003). Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial therapy. J Antimicrob Chemother 51: 1055-1065 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»